The most common side effects in the trial included: Nausea (about 29 to 42 percent of participants, depending on the dose) Diarrhea (25 to 34 percent) Constipation (24 to 26 percent) Vomiting (11 to 25 percent) Upper respiratory tract infection (12 to 14 percent) These side effects are consistent with other injectable weight loss medications, according to Siegel
The article, Glucagon Like Peptide-1 (GLP-1) Receptor Agonists: There Is No Such Thing as a Free Lunch published in the The American Journal of Medicine provides a healthy glimpse of reality with GLP-1 drug use
Van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al
GLP-1 receptor agonists (like Ozempic, Wegovy and Mounjaro) are medications that mimic the effects of this naturally existing hormone, often resulting in significant appetite reduction and reduced cravings
The Phase 2 trial demonstrated that higher doses produce greater reductions in body weight, with the 12mg group achieving 24.2% average weight loss at 48 weeks
Compounded semaglutide from pharmacies at $200 per month producing 30 to 40 pounds of weight loss over several months works out to roughly $40 to $55 per pound
.webp)
